Ainos, Inc. (NASDAQ:AIMD) Short Interest Update

Posted by Ethan Ryder on Sep 28th, 2026

Ainos, Inc. (NASDAQ:AIMD – Get Free Report) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totaling 55,787 shares, a growth of 172.6% from the August 31st total of 20,463 shares. Based on an average daily trading volume, of 33,974 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.8% of the shares of the company are sold short.

Ainos Stock Performance

AIMD opened at $1.34 on Monday. Ainos has a 1-year low of $1.25 and a 1-year high of $4.44. The stock has a market capitalization of $9.89 million, a price-to-earnings ratio of -0.53 and a beta of 2.47. The business has a 50 day moving average of $1.44 and a 200-day moving average of $1.66.

Ainos (NASDAQ:AIMD – Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.62) earnings per share (EPS) for the quarter. Ainos had a negative return on equity of 217.50% and a negative net margin of 11,912.10%.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Ainos has an average rating of “Sell”.

View Our Latest Stock Analysis on AIMD

Ainos Company Profile

(Get Free Report)

Ainos, Inc (NASDAQ: AIMD) is a healthcare technology company developing solutions in artificial intelligence, point-of-care testing and telehealth. The company focuses on technologies intended to support non-invasive disease screening, decentralized healthcare delivery and improved access to diagnostic services.

Ainos’ AI Nose platform uses artificial intelligence and analysis of volatile organic compounds to identify patterns that may be associated with certain health conditions. The company is also developing point-of-care testing products and related diagnostic applications designed for use outside traditional laboratory settings.

In addition, Ainos has worked on telehealth solutions and therapeutic products, including its VELDONA low-dose interferon-alpha platform.